DD3-ZD55-SPAG9(DD3-ZD55-SPAG9) - 药物靶点：SPAG9_在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

溶瘤病毒

别名

靶点

SPAG9

作用机制

SPAG9调节剂(sperm associated antigen 9 modulators)

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

苏州大学附属第二医院

在研机构

苏州大学附属第二医院

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 DD3-ZD55-SPAG9 相关的临床结果

登录后查看更多信息

100 项与 DD3-ZD55-SPAG9 相关的转化医学

登录后查看更多信息

100 项与 DD3-ZD55-SPAG9 相关的专利（医药）

登录后查看更多信息

1

项与 DD3-ZD55-SPAG9 相关的文献（医药）

2022-04-30·Journal of Oncology4区 · 医学

Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

4区 · 医学

ArticleOA

作者: Lu, Meng ; Mao, Li-jun ; Wei, Fu-kun ; Wu, Chuang ; Yang, Dong-rong ; Xu, Zi-yang

Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely related to tumorigenesis of PCa, and SPAG9 is a therapeutic target for PCa. In this study, a new oncolytic adenovirus DD3-ZD55-SPAG9 was constructed by using DD3 promoter to enhance the efficacy and safety of adenovirus. The combined use of DD3-ZD55-SPAG9 and docetaxel showed that DD3-ZD55-SPAG9 significantly improved the anti-tumor efficacy of docetaxel in PCa both in vitro and in vivo. The mechanism was related to the induction of tumor cell apoptosis and the inhibition of tumor cell invasion. In conclusion, DD3-ZD55-SPAG9 combined with docetaxel is an effective strategy for PCa therapy.

100 项与 DD3-ZD55-SPAG9 相关的药物交易

登录后查看更多信息